Molecular markers to individualize adjuvant therapy for colon cancer (Q37741795)

22 August 2017

1 reference

title

Molecular markers to individualize adjuvant therapy for colon cancer (English)

1 reference

22 August 2017

1

Tara Gangadhar

1 reference

22 August 2017

Richard L Schilsky

2

1 reference

PubMed ID

20440283

22 August 2017

language of work or name

English

0 references

publication date

4 May 2010

1 reference

Nature Reviews Clinical Oncology

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

6

1 reference

22 August 2017

318-325

1 reference

Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging

22 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Genetic alterations during colorectal-tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Racial and ethnic differences in advance care planning among patients with cancer: impact of terminal illness acknowledgment, religiousness, and treatment preferences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Clues to the pathogenesis of familial colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Microsatellite instability in cancer of the proximal colon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Molecular origins of cancer: Molecular basis of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Identification of a chromosome 18q gene that is altered in colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Allelic loss of chromosome 18q and prognosis in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

The paracrine hormone hypothesis of colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Expression of high p53 levels in colorectal cancer: a favourable prognostic factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Aspirin use and survival after diagnosis of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.62

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20440283

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20440283

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20440283

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2010.62

1 reference

22 August 2017

1 reference

PubMed ID

20440283